2023
DOI: 10.1002/art.42486
|View full text |Cite
|
Sign up to set email alerts
|

Reduction of Neutrophil Activation by Phosphodiesterase 4 Blockade in Behçet's Disease

Abstract: ObjectiveBehçet's disease (BD) is a systemic vasculitis with inflammatory lesions mediated by cytotoxic T cells and neutrophils. Apremilast, an orally available small‐molecule drug that selectively inhibits phosphodiesterase 4 (PDE4), has been recently approved for the treatment of BD. We aimed to investigate the effect of PDE4 inhibition on neutrophil activation in BD.MethodsWe studied surface markers and reactive oxygen species (ROS) production by flow cytometry, and neutrophil extracellular traps (NETs) pro… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
5

Relationship

0
5

Authors

Journals

citations
Cited by 6 publications
(1 citation statement)
references
References 37 publications
0
1
0
Order By: Relevance
“…Tables 1, 2 show previously reported data on innate immune responses to therapeutic treatment in BD and RP, respectively (59,(131)(132)(133)(134)(135)(136)(137)(138)(139)(140)(141)(142)(143)(144)(145)(146)(147)(148)(149).…”
Section: Innate Immune Responses In Treatment Of Bd and Rpmentioning
confidence: 99%
“…Tables 1, 2 show previously reported data on innate immune responses to therapeutic treatment in BD and RP, respectively (59,(131)(132)(133)(134)(135)(136)(137)(138)(139)(140)(141)(142)(143)(144)(145)(146)(147)(148)(149).…”
Section: Innate Immune Responses In Treatment Of Bd and Rpmentioning
confidence: 99%